Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,258,701 papers from all fields of science
Search
Sign In
Create Free Account
BIBW-2992-MA2
Known as:
BIBW 2992MA2
, BIBW-2992MA2
, BIBW2992 MA2
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Afatinib
afatinib dimaleate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients…
T. Seiwert
,
P. Clement
,
+5 authors
E. Cohen
2010
Corpus ID: 74612668
5501 Background: BIBW 2992 is a novel, potent, orally bioavailable irreversible inhibitor of EGFR/HER1 and HER2 receptor tyrosine…
Expand
Highly Cited
2007
Highly Cited
2007
Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma
C. Schütze
,
A. Dörfler
,
+5 authors
M. Krause
Strahlentherapie und Onkologie (Print)
2007
Corpus ID: 44705461
Purpose:To investigate the effect of the dual EGFR/HER2 (ErbB2) tyrosine kinase inhibitors BIBW 2992 and BIBW 2669 on…
Expand
1998
1998
Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.
C. Gaj
,
I. Anyanwutaku
,
Y. Chang
,
Y. Cheng
Biochemical Pharmacology
1998
Corpus ID: 40915059
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE